312 related articles for article (PubMed ID: 33293197)
1. A case of non-small cell lung cancer with danazol-dependent aplastic anemia induced by pembrolizumab.
Goda S; Tsuji T; Matsumoto Y; Shiotsu S; Tanaka S; Suga Y; Fujii H; Matsuyama A; Omura A; Yuba T; Takumi C; Hiraoka N
Curr Probl Cancer; 2021 Jun; 45(3):100686. PubMed ID: 33293197
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab-induced thrombotic thrombocytopenic purpura.
Dickey MS; Raina AJ; Gilbar PJ; Wisniowski BL; Collins JT; Karki B; Nguyen AD
J Oncol Pharm Pract; 2020 Jul; 26(5):1237-1240. PubMed ID: 31718453
[TBL] [Abstract][Full Text] [Related]
3. Fatal acute hepatic failure induced by danazol in a patient with endometriosis and aplastic anemia.
Hayashi T; Takahashi T; Minami T; Akaike J; Kasahara K; Adachi M; Hinoda Y; Takahashi S; Hirayama T; Imai K
J Gastroenterol; 2001 Nov; 36(11):783-6. PubMed ID: 11757752
[TBL] [Abstract][Full Text] [Related]
4. Severe Thrombocytopenia Associated With Pembrolizumab in Patients With Non-small Cell Lung Cancer (NSCLC): A Case Report and Literature Review.
Mouri A; Kaira K; Shiono A; Miura YU; Kagamu H
In Vivo; 2020; 34(2):877-880. PubMed ID: 32111798
[TBL] [Abstract][Full Text] [Related]
5. Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review.
Suliman AM; Bek SA; Elkhatim MS; Husain AA; Mismar AY; Eldean MZS; Lengyel Z; Elazzazy S; Rasul KI; Omar NE
Cancer Immunol Immunother; 2021 Apr; 70(4):935-944. PubMed ID: 33070259
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab-induced obstructive bronchiolitis in a patient with stage IV non-small-cell lung cancer.
Blanchard A; Bouchard N
Curr Oncol; 2019 Aug; 26(4):e571-e573. PubMed ID: 31548826
[TBL] [Abstract][Full Text] [Related]
7. Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol.
Liu Y; Zhang J; Yin Z; Zhu X; Xue L; Cao B
Thorac Cancer; 2020 Jul; 11(7):2023-2030. PubMed ID: 32379397
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab-induced agranulocytosis.
Fernández Martínez V; García-Avello Fernández-Cueto A; Valencia Soto CM; Barbadillo Villanueva S; Ochagavía Sufrategui M; Rioja Carrera M; Alonso Buznego LA; Valero Domínguez M
J Oncol Pharm Pract; 2024 Jun; 30(4):767-771. PubMed ID: 38291678
[TBL] [Abstract][Full Text] [Related]
9. Aplastic anemia in a lung adenocarcinoma patient receiving pemetrexed.
Matama G; Tokito T; Takeoka H; Hiraoka Y; Matsuo N; Nakamura M; Ishii H; Kinoshita T; Azuma K; Yamada K; Hoshino T
Invest New Drugs; 2017 Oct; 35(5):662-664. PubMed ID: 28361276
[TBL] [Abstract][Full Text] [Related]
10. Antithymocyte globulin for aplastic anemia secondary to pembrolizumab: a case report and review of literature.
Yeung C; Relke N; Good D; Satkunam N; Mates M
Immunotherapy; 2023 Apr; 15(5):323-333. PubMed ID: 36852421
[TBL] [Abstract][Full Text] [Related]
11. Dramatic, significant metabolic response to a one-time pembrolizumab treatment following a relapse of pre-existing organizing pneumonia in a patient with advanced non-small cell lung cancer: A case report.
Kato M; Mori M; Miura K; Asao T; Motomura H; Nishino K; Ko R; Koyama R; Hayashi T; Takahashi K
Thorac Cancer; 2021 Nov; 12(22):3076-3079. PubMed ID: 34617405
[TBL] [Abstract][Full Text] [Related]
12. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab combined with stereotactic body radiotherapy in a patient with human immunodeficiency virus and advanced non-small cell lung cancer: a case report.
Li D; He C; Xia Y; Du Y; Zhang J
J Med Case Rep; 2018 Apr; 12(1):104. PubMed ID: 29681240
[TBL] [Abstract][Full Text] [Related]
14. 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer.
Borghaei H; Langer CJ; Gadgeel S; Papadimitrakopoulou VA; Patnaik A; Powell SF; Gentzler RD; Martins RG; Stevenson JP; Jalal SI; Panwalkar A; Yang JC; Gubens M; Sequist LV; Awad MM; Fiore J; Saraf S; Keller SM; Gandhi L
J Thorac Oncol; 2019 Jan; 14(1):124-129. PubMed ID: 30138764
[TBL] [Abstract][Full Text] [Related]
15. A case of successful pembrolizumab rechallenge in a patient with non-small-cell lung cancer and grade 3 dermatomyositis.
Kartolo A; Towheed T; Mates M
Immunotherapy; 2021 Apr; 13(6):477-481. PubMed ID: 33626928
[TBL] [Abstract][Full Text] [Related]
16. [Severe aplastic anemia remarkably improved by a treatment with antilymphocyte globulin, high-dose methylprednisolone and danazol].
Miyamura K; Kojima S; Takeyama K; Matsushita T; Minami S; Kodera Y
Rinsho Ketsueki; 1989 Jan; 30(1):72-7. PubMed ID: 2716202
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia.
Kojima S; Hibi S; Kosaka Y; Yamamoto M; Tsuchida M; Mugishima H; Sugita K; Yabe H; Ohara A; Tsukimoto I
Blood; 2000 Sep; 96(6):2049-54. PubMed ID: 10979946
[TBL] [Abstract][Full Text] [Related]
18. Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature.
Cosimati A; Rossi L; Didona D; Forcella C; Didona B
J Oncol Pharm Pract; 2021 Apr; 27(3):727-733. PubMed ID: 32772795
[TBL] [Abstract][Full Text] [Related]
19. Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring.
Katsume Y; Isawa T; Toi Y; Fukuda R; Kondo Y; Sugawara S; Ootomo T
Intern Med; 2018 Nov; 57(21):3157-3162. PubMed ID: 29877257
[TBL] [Abstract][Full Text] [Related]
20. Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus.
Jono M; Kinehara Y; Utsu Y; Tamura Y; Koseto M; Murakami T; Uota A; Ninomiya R; Komo S; Sumitani S; Sato B; Kasayama S; Tachibana I
Intern Med; 2020 Feb; 59(4):569-572. PubMed ID: 31666468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
